Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya.

समान संसाधन

• Biodistribution and persistence of an MVA-vectored candidate HIV vaccine in SIV-infected rhesus macaques and SCID mice.
  द्वारा: Hanke, T, और अन्य
  प्रकाशित: (2005)
• Cardiac Safety in Clinical Trials with Preventive HIV Vaccine Candidates Based on Modified Vaccinia Ankara (MVA)
  द्वारा: Schmidt, C, और अन्य
  प्रकाशित: (2008)
• Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity.
  द्वारा: Peters, B, और अन्य
  प्रकाशित: (2007)
• Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate.
  द्वारा: Jeffrey R Currier, और अन्य
  प्रकाशित: (2010-11-01)
• Safety and immunogenicity of IMVAMUNE®, a third-generation vaccine based on the modified vaccinia Ankara (MVA) strain
  द्वारा: L. F. Stovba, और अन्य
  प्रकाशित: (2023-04-01)